Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. The Company is currently developing ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.

A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects as pertains to the facts that: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to contact Joshua H. Grabar at jgrabar@grabarlaw.com or Mia R. Heller at mheller@grabarlaw.com, or call 267-507-6085.